| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.19 | 0.001 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.002 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.002 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |